<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11750131</article-id><article-id pub-id-type="pmcid-ver">PMC11750131.1</article-id><article-id pub-id-type="pmcaid">11750131</article-id><article-id pub-id-type="pmcaiid">11750131</article-id><article-id pub-id-type="manuscript-id">NIHMS2026652</article-id><article-id pub-id-type="pmid">39341602</article-id><article-id pub-id-type="doi">10.1016/j.josat.2024.209524</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2026652</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2026652</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Health Service Utilization, Substance Use Treatment Response, and Death in Patients with Opioid Use Disorder and Comorbid Hepatitis C Findings from Prospective Cohort Study with Administrative Database Linkage</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dennis</surname><given-names initials="BB">Brittany B.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Babe</surname><given-names initials="G">Glenda</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gayowsky</surname><given-names initials="A">Anastasia</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosic</surname><given-names initials="T">Tea</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names initials="M">Myanca</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bach</surname><given-names initials="P">Paxton</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perez</surname><given-names initials="R">Richard</given-names></name><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Oliveira</surname><given-names initials="C">Claire</given-names></name><xref rid="A7" ref-type="aff">7</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A9" ref-type="aff">9</xref><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samet</surname><given-names initials="J">Jeffrey</given-names></name><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weaver</surname><given-names initials="V">Victoria</given-names></name><xref rid="A12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Young</surname><given-names initials="S">Samantha</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dionne</surname><given-names initials="J">Joanna</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmed</surname><given-names initials="A">Aijaz</given-names></name><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="D">Donghee</given-names></name><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thabane</surname><given-names initials="L">Lehana</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A14" ref-type="aff">14</xref><xref rid="A15" ref-type="aff">15</xref><xref rid="A16" ref-type="aff">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samaan</surname><given-names initials="Z">Zainab</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A17" ref-type="aff">17</xref></contrib></contrib-group><aff id="A1"><label>1.</label>British Columbia Centre on Substance Use, Vancouver BC, Canada</aff><aff id="A2"><label>2.</label>Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver BC, Canada</aff><aff id="A3"><label>3.</label>Department of Medicine, McMaster University, Hamilton ON, Canada</aff><aff id="A4"><label>4.</label>ICES McMaster, McMaster University, Hamilton, Ontario, Canada</aff><aff id="A5"><label>5.</label>Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton ON Canada</aff><aff id="A6"><label>6.</label>Department of Psychiatry, University of Ottawa, Ontario, Canada</aff><aff id="A7"><label>7.</label>Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff><aff id="A8"><label>8.</label>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff><aff id="A9"><label>9.</label>ICES, Toronto, Canada</aff><aff id="A10"><label>10.</label>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada</aff><aff id="A11"><label>11.</label>Department of Medicine, Boston University, Boston, USA</aff><aff id="A12"><label>12.</label>Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC, Canada</aff><aff id="A13"><label>13.</label>Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, California USA</aff><aff id="A14"><label>14.</label>Biostatistics Unit, Research Institute at St Joseph&#8217;s Healthcare, Hamilton, Ontario, Canada</aff><aff id="A15"><label>15.</label>Departments of Pediatrics/Anesthesia, McMaster University, Hamilton, Ontario, Canada</aff><aff id="A16"><label>16.</label>Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa</aff><aff id="A17"><label>17.</label>Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author Contribution</p><p id="P2">BBD and ZS are responsible for the study concept and design. BBD, GB, RP, CdO and ZS developed the methods and statistical analysis plan. GB conducted data linkage and statistical analyses. BBD wrote the first draft of the manuscript and BBD, GB, AG, SY, MR, RP, CdO, TR, PB, VW, JD, AA, DK, LT, and ZS contributed to writing and critically revising the final manuscript. All authors reviewed and approved the final manuscript.</p></fn><corresp id="CR1"><bold>Corresponding Author: Dr. Brittany Dennis</bold>, Clinician Scientist, BC Centre on Substance Use (<italic toggle="yes">BCCSU</italic>), Assistant Professor, Department of Medicine, Division of Social Medicine, University of British Columbia BCCSU Offices: 400-1045 <italic toggle="yes">Howe St</italic>, Vancouver, BC V6Z 2A9 Canada</corresp><fn fn-type="COI-statement" id="FN3"><p id="P44"><bold>Declarations of Interest</bold>: None. The authors have no declarations of interest to report.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>9</month><year>2024</year></pub-date><volume>167</volume><issue-id pub-id-type="pmc-issue-id">480029</issue-id><fpage>209524</fpage><lpage>209524</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>10</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 03:25:36.623"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2026652.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P3">Among patients with opioid use disorder (OUD), high rates of overdose and death have been reported in subgroups with Hepatitis C Virus (HCV). Evidence on the comorbid effect of HCV on clinical and substance use trajectories has been limited by small sample sizes, short follow-up, and heavy reliance on administrative data which lacks granularity on important prognostic factors. Additionally, few studies include populations on substance use treatment.</p></sec><sec id="S2"><title>Aim:</title><p id="P4">To establish the impact of HCV exposure (antibody positivity) on health care utilization patterns, substance use treatment response, and death in a cohort of patients with OUD on opioid agonist therapy (OAT).</p></sec><sec id="S3"><title>Methods:</title><p id="P5">This multi-center prospective cohort study recruited adult patients with OUD on OAT from 57 substance use treatment centers in Ontario, Canada. The study collected substance use outcomes, and classified patients with &#8805; 50% positive opioid urine screens over one year of follow-up as having poor treatment response. Additional data obtained via linkage with ICES administrative databases evaluated the relationship between HCV status, healthcare service utilization, and death over 3 years of follow-up. Multiple logistic regression models established the adjusted impact of HCV on various outcomes.</p></sec><sec id="S4"><title>Results:</title><p id="P6">Among recruited participants (n=3430), 44.10% were female with a mean age of 38.64 years (Standard deviation: 10.96). HCV was prevalent in 10.6% of the cohort (n=365). Methadone was used most often (83.9%, n=2876), followed by sublingual buprenorphine (16.2%, n=554). Over the three-year follow-up, 5.3% of patients died (n=181). Unadjusted results reveal rates of hospitalization (all-cause, mental-health related, critical care) and emergency department visits (mental health-related), were significantly higher among HCV patients. Associations diminished in adjusted models. Active injection drug use exhibited the highest predictive risk for all outcomes.</p></sec><sec id="S5"><title>Conclusion:</title><p id="P7">A high degree of acute physical and mental illness and its resulting health service utilization burden is concentrated among patients with OUD and comorbid HCV. Future research should explore the role for targeted interventions and how best to implement integrated healthcare models to better address the complex health needs of HCV populations who inject drugs.</p></sec></abstract><kwd-group><kwd>liver disease</kwd><kwd>opioid agonist therapy</kwd><kwd>injection use</kwd><kwd>intravenous drug use (IVDU)</kwd><kwd>hepatitis C virus</kwd><kwd>methadone</kwd><kwd>methadone maintenance treatment</kwd><kwd>medication assisted therapy</kwd><kwd>buprenorphine</kwd><kwd>opioid addiction</kwd><kwd>opioid abuse</kwd><kwd>opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>